Caterpillar bids for Australia’s RPMGlobal- AFR
Chemed Corp (NYSE:CHE) Executive Vice President Nicholas Michael Westfall sold 10,012 shares of company stock on August 4, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $421.91, for a total transaction value of $4,224,162. The transaction comes as the stock trades near its 52-week low of $408.42, having declined about 9% in the past week.
The prices for the sales ranged from $421.00 to $426.16. Following the transaction, Westfall directly owns zero shares of Chemed Corp. While this insider sale might raise concerns, InvestingPro analysis shows the company maintains a GOOD financial health score, with management actively buying back shares. Get deeper insights into insider trading patterns and 10+ more exclusive ProTips with an InvestingPro subscription.
In other recent news, Chemed Corporation reported its second-quarter 2025 earnings, which did not meet analysts’ expectations. The earnings per share were $4.27, falling short of the anticipated $5.39. Additionally, revenue was reported at $618.8 million, below the projected $650.6 million. These results were a significant development for investors keeping an eye on the company’s financial performance. In related news, VITAS Healthcare, a subsidiary of Chemed, announced a leadership change. Nicholas M. Westfall has stepped down as chairman and CEO to pursue other opportunities. Joel L. Wherley, who was serving as president and chief operating officer, will now take over as CEO. These recent developments are crucial for investors monitoring Chemed Corporation and its subsidiary’s strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.